Published in Semin Vasc Med on November 01, 2004
Rho GTPases and the actin cytoskeleton. Science (1998) 28.19
Rho GTPases and signaling networks. Genes Dev (1997) 11.70
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res (1994) 8.57
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med (2001) 7.51
Apoptosis in the failing human heart. N Engl J Med (1997) 6.35
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med (2000) 5.72
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation (1998) 5.11
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest (1995) 5.09
Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem (1998) 3.97
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 3.23
Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension (1998) 2.70
Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation (2002) 2.57
Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 2.30
Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem (1995) 2.27
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest (2001) 2.19
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail (1997) 2.08
HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension (2001) 1.84
Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest (1999) 1.82
Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem (1999) 1.73
MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO J (1997) 1.66
Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J (1998) 1.65
Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation (1999) 1.62
Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res (2003) 1.59
Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest (2000) 1.58
Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem (1996) 1.57
HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol (2000) 1.56
Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem (1996) 1.48
Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation (2001) 1.47
Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation (1990) 1.42
Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol (1999) 1.39
Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation (1997) 1.38
Bradykinin-regulated interactions of the mitogen-activated protein kinase pathway with the endothelial nitric-oxide synthase. J Biol Chem (2000) 1.35
Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol (1995) 1.32
The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. J Am Coll Cardiol (2002) 1.28
A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. J Clin Invest (1998) 1.27
Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res (1995) 1.24
Signalling pathways in cardiac myocyte hypertrophy. Ann Med (2001) 1.18
Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res (1996) 1.16
Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation (2001) 1.13
Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation (2001) 1.03
Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol (2002) 1.00
Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes. J Biol Chem (1998) 0.97
Studies on the function of rho A protein in cardiac myofibrillogenesis. J Cell Biochem (1997) 0.95
Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. Am J Physiol Heart Circ Physiol (2001) 0.94
Stage-specific differential activation of mitogen-activated protein kinases in hypertrophied and failing rat hearts. J Mol Cell Cardiol (2001) 0.91
Heart failure, redox alterations, and endothelial dysfunction. Hypertension (2001) 0.91
Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure. J Am Coll Cardiol (2002) 0.87
Simvastatin preserves cardiac function in genetically determined cardiomyopathy. J Cardiovasc Pharmacol (2004) 0.83
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol (2003) 0.81
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation (2008) 3.48
Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol (2004) 3.18
Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med (2002) 3.17
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med (2008) 2.68
Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol (2006) 2.61
Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res (2002) 2.53
Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol (2003) 2.39
Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation (2002) 2.39
Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 2.30
Essential role of endothelial Notch1 in angiogenesis. Circulation (2005) 2.28
Rho GTPases, statins, and nitric oxide. Circ Res (2005) 2.21
Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J (2010) 2.13
Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke (2005) 2.13
Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation (2005) 2.09
Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. Proc Natl Acad Sci U S A (2002) 2.04
Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1. Circ Res (2008) 2.04
Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A (2006) 2.02
ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest (2008) 1.92
Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res (2006) 1.91
Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys (2005) 1.91
Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res (2006) 1.84
Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci U S A (2006) 1.79
NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol (2003) 1.75
Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol (2003) 1.75
Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation (2004) 1.73
RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J (2010) 1.67
Long-term statin use and psychological well-being. J Am Coll Cardiol (2003) 1.66
FHL2/SLIM3 decreases cardiomyocyte survival by inhibitory interaction with sphingosine kinase-1. Circ Res (2006) 1.63
Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol (2010) 1.62
Targeting eNOS for stroke protection. Trends Neurosci (2004) 1.60
Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res (2003) 1.59
Smooth muscle Notch1 mediates neointimal formation after vascular injury. Circulation (2009) 1.58
Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol (2007) 1.46
Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation (2005) 1.45
Noninvasive method for assessing the human circadian clock using hair follicle cells. Proc Natl Acad Sci U S A (2010) 1.43
Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal (2009) 1.43
Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice. FASEB J (2008) 1.41
Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol (2002) 1.41
Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest (2010) 1.40
Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest (2002) 1.40
Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation (2007) 1.39
11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression. Bioorg Med Chem Lett (2003) 1.38
Increased vascular senescence and impaired endothelial progenitor cell function mediated by mutation of circadian gene Per2. Circulation (2008) 1.36
NF-κB and innate immunity in ischemic stroke. Ann N Y Acad Sci (2010) 1.34
Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol (2007) 1.33
Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab (2006) 1.32
Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J Clin Invest (2006) 1.31
Linking Notch signaling to ischemic stroke. Proc Natl Acad Sci U S A (2008) 1.28
A mouse model of diet-induced obesity and insulin resistance. Methods Mol Biol (2012) 1.27
A method for measuring Rho kinase activity in tissues and cells. Methods Enzymol (2008) 1.27
ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev Cardiovasc Ther (2005) 1.25
Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today (2010) 1.24
Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res (2008) 1.24
1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res (2002) 1.20
Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol (2003) 1.19
Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis (2008) 1.19
Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des (2004) 1.19
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab (2005) 1.18
Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci (2011) 1.17
Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol (2003) 1.14
Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation (2002) 1.11
Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep (2003) 1.11
Distribution of sphingosine kinase activity and mRNA in rodent brain. J Neurochem (2007) 1.11
Transcription factor CHF1/Hey2 suppresses cardiac hypertrophy through an inhibitory interaction with GATA4. Am J Physiol Heart Circ Physiol (2006) 1.10
Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des (2009) 1.09
Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol (2008) 1.09
Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol (2002) 1.08
Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion. PLoS One (2012) 1.08
Notch1 in bone marrow-derived cells mediates cardiac repair after myocardial infarction. Circulation (2011) 1.06
Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res (2004) 1.05
Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des (2009) 1.04
Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg (2004) 1.03
Functional interaction of endothelial nitric oxide synthase with a voltage-dependent anion channel. Proc Natl Acad Sci U S A (2002) 1.03
Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol (2006) 1.02
Notch signaling regulates endothelial progenitor cell activity during recovery from arterial injury in hypercholesterolemic mice. Circulation (2010) 1.02
Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol (2004) 1.01
Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J Cereb Blood Flow Metab (2008) 1.00
Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2011) 1.00
Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci Signal (2008) 0.99
Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis (2010) 0.99
Absence of TRAM restricts Toll-like receptor 4 signaling in vascular endothelial cells to the MyD88 pathway. Circ Res (2006) 0.98
Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids (2002) 0.98
gamma-Secretase inhibitor reduces diet-induced atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun (2009) 0.98
A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med (2003) 0.97
Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem Pharmacol (2006) 0.96
Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal (2013) 0.96
FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J (2012) 0.95
Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Curr Opin Pharmacol (2010) 0.95
Drug Insight: statins and stroke. Nat Clin Pract Cardiovasc Med (2005) 0.94
Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis. Circulation (2012) 0.93
Nontranscriptional actions of the glucocorticoid receptor. J Mol Med (Berl) (2003) 0.92
Increased leukocyte rho kinase (ROCK) activity and endothelial dysfunction in cigarette smokers. Hypertens Res (2010) 0.92
Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens (2011) 0.91
Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res (2008) 0.90
Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol (2008) 0.90
Vascular protection by estrogen in ischemia-reperfusion injury requires endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol (2002) 0.89
Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis. Hum Mol Genet (2011) 0.89
Notch signaling as an important mediator of cardiac repair and regeneration after myocardial infarction. Trends Cardiovasc Med (2010) 0.88
Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler Thromb Vasc Biol (2003) 0.88
Pitavastatin-induced angiogenesis and arteriogenesis is mediated by Notch1 in a murine hindlimb ischemia model without induction of VEGF. Lab Invest (2011) 0.87